Quince Therapeutics (NASDAQ:QNCX) Earns Buy Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX - Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital currently has a $4.00 price objective on the stock.

Several other research firms also recently weighed in on QNCX. Wall Street Zen downgraded Quince Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Oppenheimer initiated coverage on Quince Therapeutics in a research report on Monday, March 24th. They issued an "outperform" rating and a $10.00 target price for the company. One analyst has rated the stock with a sell rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $8.00.

Quince Therapeutics Trading Up 3.3%

Shares of NASDAQ:QNCX traded up $0.06 during midday trading on Thursday, reaching $1.89. 159,826 shares of the company's stock were exchanged, compared to its average volume of 314,336. The firm's 50 day simple moving average is $1.31 and its two-hundred day simple moving average is $1.37. The company has a debt-to-equity ratio of 0.82, a current ratio of 4.05 and a quick ratio of 4.05. The stock has a market cap of $85.94 million, a price-to-earnings ratio of -1.36 and a beta of 0.96. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.10). As a group, sell-side analysts forecast that Quince Therapeutics will post -1.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Quince Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Ieq Capital LLC purchased a new stake in Quince Therapeutics during the first quarter worth approximately $1,073,000. Virtu Financial LLC lifted its stake in Quince Therapeutics by 48.4% in the first quarter. Virtu Financial LLC now owns 43,332 shares of the company's stock valued at $58,000 after buying an additional 14,128 shares during the last quarter. Intellectus Partners LLC purchased a new stake in Quince Therapeutics in the first quarter valued at approximately $71,000. Two Sigma Investments LP purchased a new stake in Quince Therapeutics in the fourth quarter valued at approximately $57,000. Finally, Shay Capital LLC lifted its stake in Quince Therapeutics by 60.8% in the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company's stock valued at $518,000 after buying an additional 104,616 shares during the last quarter. Hedge funds and other institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.